A large cohort study of nearly 1000 women with multiple sclerosis (MS) found that menopause does not accelerate disability progression or increase the risk of transitioning to secondary progressive MS.
...
In a phase 3 trial, tolebrutinib, an oral Bruton’s tyrosine kinase inhibitor, significantly reduced the risk of sustained disability progression in patients with nonrelapsing secondary progressive multiple...
A systematic review and meta-analysis examined the clinical differences between adult patients with neuromyelitis optica spectrum disorders and those with multiple sclerosis.
Researchers set out to determine whether renal function could be used as both a predictor of relapse risk for patients with their first onset of aquaporin-4 (AQP4)-immunoglobulin G (IgG)-seropositive...
Catch up on the latest COVID-19 news in this week’s roundup! Coverage includes the efficacy and safety of sotrovimab as a COVID-19 treatment, recommendations on the management of myocardial sequelae,...
In a recent study, researchers investigated whether women with multiple sclerosis have an increased risk of relapse after pregnancy, and whether this risk is impacted by breastfeeding or disease-modifying...
In a recent study, researchers investigated whether women with multiple sclerosis have an increased risk of relapse after pregnancy, and whether this risk is impacted by breastfeeding or disease-modifying...
After identifying 3 neuroprotective drugs acting on different axonal pathobiologies, the researchers assessed each drug’s efficacy on percentage brain volume change among patients with secondary progressive...
